Inhibrx Biosciences (INBX) Total Current Liabilities (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Total Current Liabilities data on file, last reported at $33.8 million in Q4 2025.

• On a quarterly basis, Total Current Liabilities fell 17.02% year-over-year to $33.8 million in Q4 2025; TTM through Dec 2025 was $33.8 million, a 17.02% decrease from a year earlier, with the FY2025 full-year figure at $33.8 million, down 17.02% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $33.8 million, down from $36.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for INBX reached as high as $56.3 million in Q4 2023 and fell as low as $33.8 million in Q4 2025.
• Historically, Total Current Liabilities has averaged $41.6 million across 3 years, with a median of $39.9 million in 2024.
• Across the five-year window, Total Current Liabilities retreated 27.67% in 2024 and declined 0.29% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $56.3 million in 2023, then slipped by 27.67% to $40.7 million in 2024, then retreated by 17.02% to $33.8 million in 2025.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $33.8 million in Q4 2025, $36.0 million in Q3 2025, and $38.9 million in Q2 2025.